NASDAQ:RZLT

Rezolute Q4 2026 Earnings Results & Report

Rezolute logo
$4.01 +0.43 (+12.01%)
Closing price 04:00 PM Eastern
Extended Trading
$4.01 +0.00 (+0.10%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rezolute missed analyst earnings expectations in its Q4 2026 results, released September 24, 2026. The company reported EPS of -$0.20 versus the -$0.1479 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2026
Time
After Market Closes
Conference Call
4:00 PM ET

Rezolute EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.1479
Beat/Miss
Missed by -$0.0522
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Rezolute Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rezolute Q4 2026 Earnings FAQ

Rezolute (NASDAQ:RZLT) reported earnings of -$0.20 per share for Q4 2026, missing the consensus estimate of -$0.1479. The report was announced on Thursday, September 24, 2026.

Rezolute Earnings Headlines

Rezolute stock rises on positive Phase 3 upLIFT trial results
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Rezolute Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rezolute? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rezolute and other key companies, straight to your email.

About Rezolute

Rezolute (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar.

The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Rezolute is led by CEO Nevan Elam. Its drug candidates remain in development and are not approved treatments.

View Rezolute Profile